Supply / Manufacturing · GCC · Announced 20 Oct 2026
Eli Lilly → Mubadala Bio
Supply / Manufacturing deal between Eli Lilly (United States) and Mubadala Bio (United Arab Emirates), announced 20 Oct 2026. Value: Undisclosed.
Parties: Eli Lilly and Company (United States) → Mubadala Bio (United Arab Emirates)
- Deal type
- Supply / Manufacturing
- Value
- Undisclosed
- Territory
- Abu Dhabi, UAE (KEZAD site serving UAE, regional and global markets)
- Therapeutic area
- Metabolic / Diabetes
- Asset
- Localised packaging and logistics of Lilly's GLP-1 medicines (Mounjaro / tirzepatide; Foundayo / orforglipron)
- Announced
- 20 Oct 2026
Our analysis
Why this matters.
Mubadala Bio — the life sciences platform of Abu Dhabi's sovereign investor — has signed a strategic agreement with Eli Lilly to localise the packaging and logistics of Lilly's GLP-1 medicines in Abu Dhabi . Announced at the Abu Dhabi Future Health Summit and witnessed by the Director General of the Emirates Drug Establishment, it is the most prominent anchor yet for Abu Dhabi's ambition to become a global life sciences hub — and it lands on the world's most supply-constrained drug class.
The full analysis is free to read with a work email on this page.
Source: ZAWYA